- Data presented at American Heart Association Annual Scientific Sessions -
NEW ORLEANS, Nov. 10 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, presented data today demonstrating that an injection of an emulsified version of their ECM Technology(TM) improved cardiac function.
The study tested the hypothesis that an injection of ECM emulsion into infarcted myocardium would promote wound healing and angiogenesis by naturally recruiting c-kit positive cells. The study involved rats that were subjected to 45 minutes of coronary occlusion, followed by three, seven, 21 and 42 days of reperfusion with and without the ECM emulsion injection, respectively.
"Reinforcing our earlier findings, the subjects that received the emulsified ECM injection over an extended period showed significant reversal of cardiac damage and improvement in overall function following the induced occlusion," said Robert G. Matheny, M.D., Chief Scientific Officer. "The improved heart function we observed at 42 days is consistent with prior data and further demonstrates the technology's promise and sustainability," added Matheny.
At seven days post reperfusion, the population of c-kit positive cells
within the emulsion area increased significantly compared to the control
(32+/-0.6 vs. 15+/-3/1000 nuclei) and myofibroblasts accumulated in the
emulsion region to a significant extent (59+/-8 vs. 30+/-3/HPF).
Angiogenesis in the emulsion area was significantly enhanced, evidenced by
increased density value of a-SMA-positive vessels (70+/-10 vs. 20+/-4/HPF)
and vWF-positive vessels (95+/-14 vs. 34+/-8/HPF). At 42 days post
reperfusion, echocardiography showed improvements in end-systolic volume
(0.3+/-0.1 vs. 0.6+/-0.3 ml), fractional shortening (33+/-5 vs. 24+/-6) and
|SOURCE CorMatrix Cardiovascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved